Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies

Table 1 Baseline characteristics, follow-up, and clinical outcome n (%)

Parameter	Baseline period	Study period	P value
Age, median (range)	75 (23-89)	68 (49-89)	0.07
Gender (M/F)	11/9	19/25	0.43
Study patients (n)	20	44
Tumor location (n)
Stomach	18	40
Duodenum	2	4
Tumor size (mm), median (range)	60 (12-200)	38 (13-220)	0.29
Tumor endosonographic appearance
Homogenous (solid)	8	17
Heterogeneous (necrotic)	12	27
EUS-FNA (n)	16	38
Needle (22 G/25 G)	12/4	26/12	0.75
Passes (n), median (range)	2 (1-3)	3 (1-4)	0.10
EUS-FNB (n)	7	44
Needle (TCB 19 G/FNB 19 G/FNB 22 G)	7/0/0	0/5/39	< 0.001
Passes (n), median (range)	1 (1-4)	2 (1-4)	0.15
ROSE1	9 (56)	26 (68)	0.53
Study cytologist	5 (31)	32 (84)	< 0.001
Study pathologist	2 (29)	38 (86)	0.003
Resected cases	15 (75)	27 (61)	0.40
Resection margin (R0/R1/R2)	13/1/1	24/3/0
Follow-up time2, mo (range)	72 (16-105)	19 (1-45)
Overall survival (OS)3, 12 mo	20/20 (100)	31/31 (100)	1.00
OS, 24 mo	19/20 (95)	17/18 (94)	1.00
OS, 36 mo	18/20 (90)	10/11 (91)	1.00
Patients deceased	9/20 (45)	2/44 (5)

¹Rapid on-site cytology evaluation by a cytotechnician;

²From the date of EUS until death or until end of follow-up;

³From the date of EUS until 12, 24 and 36 mo post-EUS. EUS: Endoscopic ultrasound; FNA: Fine needle aspiration; FNB: Fine needle biopsy.